Search details
1.
Fibroblast growth factor receptor 1/Klothoß agonist BFKB8488A improves lipids and liver health markers in patients with diabetes or NAFLD: A phase 1b randomized trial.
Hepatology
; 78(3): 847-862, 2023 09 01.
Article
in English
| MEDLINE | ID: mdl-35993161
2.
Meta-Analysis of 49 Roche Oncology Trials Comparing Blinded Independent Central Review (BICR) and Local Evaluation to Assess the Value of BICR.
Oncologist
; 2023 Mar 11.
Article
in English
| MEDLINE | ID: mdl-36905580
3.
The oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with hormone receptor-positive HER2-negative (HR + /HER2 -) advanced/metastatic breast cancer.
Breast Cancer Res Treat
; 197(2): 319-331, 2023 Jan.
Article
in English
| MEDLINE | ID: mdl-36401732
4.
Deep Ensembles Are Robust to Occasional Catastrophic Failures of Individual DNNs for Organs Segmentations in CT Images.
J Digit Imaging
; 36(5): 2060-2074, 2023 10.
Article
in English
| MEDLINE | ID: mdl-37291384
5.
Heart and bladder detection and segmentation on FDG PET/CT by deep learning.
BMC Med Imaging
; 22(1): 58, 2022 03 30.
Article
in English
| MEDLINE | ID: mdl-35354384
6.
Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors.
Invest New Drugs
; 38(2): 419-432, 2020 04.
Article
in English
| MEDLINE | ID: mdl-31020608
7.
Tumor Segmentation and Feature Extraction from Whole-Body FDG-PET/CT Using Cascaded 2D and 3D Convolutional Neural Networks.
J Digit Imaging
; 33(4): 888-894, 2020 08.
Article
in English
| MEDLINE | ID: mdl-32378059
8.
Clinical translation of ferumoxytol-based vessel size imaging (VSI): Feasibility in a phase I oncology clinical trial population.
Magn Reson Med
; 77(2): 814-825, 2017 02.
Article
in English
| MEDLINE | ID: mdl-26918893
9.
Phase Ia/b Study of Giredestrant ± Palbociclib and ± Luteinizing Hormone-Releasing Hormone Agonists in Estrogen Receptor-Positive, HER2-Negative, Locally Advanced/Metastatic Breast Cancer.
Clin Cancer Res
; 30(4): 754-766, 2024 02 16.
Article
in English
| MEDLINE | ID: mdl-37921755
10.
An Open-label Phase I Study of GDC-0927 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer.
Clin Cancer Res
; 29(15): 2781-2790, 2023 08 01.
Article
in English
| MEDLINE | ID: mdl-37261814
11.
Phase I study of the anti-α5ß1 monoclonal antibody MINT1526A with or without bevacizumab in patients with advanced solid tumors.
Cancer Chemother Pharmacol
; 82(2): 339-351, 2018 08.
Article
in English
| MEDLINE | ID: mdl-29905898
12.
FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1-Selected Patients With NSCLC.
J Thorac Oncol
; 13(11): 1733-1742, 2018 11.
Article
in English
| MEDLINE | ID: mdl-29775807
13.
18F-Fluoroestradiol PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent Trials.
Clin Cancer Res
; 23(12): 3053-3060, 2017 Jun 15.
Article
in English
| MEDLINE | ID: mdl-28011460
14.
Treatment with a human recombinant monoclonal IgG antibody against oxidized LDL in atherosclerosis-prone pigs reduces cathepsin S in coronary lesions.
Int J Cardiol
; 215: 506-15, 2016 Jul 15.
Article
in English
| MEDLINE | ID: mdl-27135822
15.
Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors.
Clin Cancer Res
; 22(12): 2874-84, 2016 06 15.
Article
in English
| MEDLINE | ID: mdl-26787751
16.
Splenic metabolic activity predicts risk of future cardiovascular events: demonstration of a cardiosplenic axis in humans.
JACC Cardiovasc Imaging
; 8(2): 121-30, 2015 Feb.
Article
in English
| MEDLINE | ID: mdl-25577441
17.
First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors.
Clin Cancer Res
; 21(1): 77-86, 2015 Jan 01.
Article
in English
| MEDLINE | ID: mdl-25370471
18.
Correction: 18F-Fluoroestradiol PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent Trials.
Clin Cancer Res
; 25(4): 1435, 2019 Feb 15.
Article
in English
| MEDLINE | ID: mdl-30770494
19.
Quantitative model of the relationship between dipeptidyl peptidase-4 (DPP-4) inhibition and response: meta-analysis of alogliptin, saxagliptin, sitagliptin, and vildagliptin efficacy results.
J Clin Pharmacol
; 52(10): 1494-505, 2012 Oct.
Article
in English
| MEDLINE | ID: mdl-22162539
20.
Selective modulation of PPARγ activity can lower plasma glucose without typical thiazolidinedione side-effects in patients with Type 2 diabetes.
J Diabetes Complications
; 25(3): 151-8, 2011.
Article
in English
| MEDLINE | ID: mdl-20739195